

FORM PTO-1449 (REV. 7-80)				U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO. 3015/6/US		SERIAL NO. 10/021780	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)								APPLICANT Anantanarayan et al.			
								FILING DATE 12/07/01		GROUP 1624	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Y0	1	3,254,093	05/1966	Huisgen et al.	260	295	
	2	3,984,431	10/1976	Gueremy et al.	280	310	
	3	4,000,281	12/1976	Beiler et al.	424	283	
	4	5,051,518	09/1991	Murray et al.	548	373	
	5	5,134,142	07/1992	Matsuo et al.	514	255	
	6	5,559,137	09/1996	Adams et al.	514	341	
	7	5,486,534	01/1996	Lee et al.	514	406	
	8	5,589,439	12/1996	Goto et al.	504	261	
	9	5,658,903	08/1997	Adams et al.	514	235.8	
	10	5,739,143	04/1998	Adams et al.	514	275	
	11	5,756,529	05/1998	Isakson et al.	514	406	
	12	5,972,972	10/1999	Mihelich et al.	514	341	
	V	13	5,998,425	12/1999	Adams et al.	514	275

FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
Y0	14	WO 83/00330	02/1983	PCT			YES NO
	15	WO 92/19615	11/1992	PCT			
	16	WO 95/06036	03/1995	PCT			
	17	WO 95/22545 A1	08/1995	PCT			
	18	WO 96/03385 A1	02/1996	PCT			
	V						

EXAMINER <u>T. A. Solola</u>	DATE CONSIDERED <u>6-4-03</u>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (REV. 7-80)					U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 3015/6/US		SERIAL NO. 10/021780	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)							APPLICANT Anantanarayan et al.			
							FILING DATE 12/07/01		GROUP 1626	
19	WO 96/21452 A1	07/1996	PCT							
20	WO 96/21654 A1	07/1996	PCT							
21	WO 96/40143 A1	12/1996	PCT							
22	WO 97/01551	01/1997	PCT							
23	WO 97/23479 A1	07/1997	PCT							
24	WO 97/25046 A1	07/1997	PCT							
25	WO 97/25047 A1	07/1997	PCT							
26	WO 97/25048 A1	07/1997	PCT							
27	WO 97/32583 A1	09/1997	PCT							
28	WO 97/35855 A1	10/1997	PCT							
29	WO 97/35856 A1	10/1997	PCT							
30	WO 97/47618 A1	12/1997	PCT							
31	WO 98/07425 A1	02/1998	PCT							
32	WO 98/16230 A1	04/1998	PCT							
33	WO 98/25619 A1	06/1998	PCT							
34	WO 98/52937 A2 & A3	11/1998	PCT							
35	WO 98/52940 A1	11/1998	PCT							
36	WO 98/52941 A1	11/1998	PCT							
37	WO 98/57968 A1	12/1998	PCT							
38	WO 99/01130 A1	01/1999	PCT							
39	WO 99/01131 A1	01/1999	PCT							
40	WO 99/01136 A1	01/1999	PCT							

EXAMINER T. A. Solola	DATE CONSIDERED 6-4-03
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 (REV. 7-80)					U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 3015/6/US		SERIAL NO. 10/021780	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)							APPLICANT Anantanarayan et al.			
							FILING DATE 12/07/01		GROUP 1626	
40	41	WO 99/01452 A1	01/1999	PCT						
	42	WO 99/17776 A1	04/1999	PCT						
	43	WO 99/32121 A1	07/1999	PCT						
	44	WO 99/61426 A1	12/1999	PCT						
	45	0 115 640 A2	12/1983	EPO						
	46	0 418 845 A1	03/1991	EPO						
	47	0 515 041 A2	11/1992	EPO						
	48	0 531 901 A2	03/1993	EPO						
	49	4-145081	05/1992	JAPAN						X
	50	5-17470	01/1993	JAPAN						X
	51	5-345772	12/1993	JAPAN						X
	52	8-183787	07/1996	JAPAN						X
	53	WO 94/19350	09/1994	PCT						
	54	WO 95/31451	11/1995	PCT						
	55	0 846 686 A1	06/1998	EPO						
	56	0 846 687 A1	06/1998	EPO						
	57	DD 295 374 A5	10/1991	GERMANY						

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)		
40	58	Boehm, J.C. et al., "New Inhibitors Of p38 Kinase", Exp. Opin. Ther. Patents, Vol. 10(1), pp. 25-36, (2000) ✓
	59	Laszlo, S.E. et al., "Pyrroles And Other Heterocycles As Inhibitors Of p38 Kinase", <i>Bioorganic & Medicinal Chemistry Letters</i> 8, pp. 2689-2694, 1998. ✓
	60	Dannhardt G. et al., "ω-Aminopropyl-pyrazole durch Ringtransformation von Enaminonen der Pyrrolidinreihe", Arch. Pharm., Vol. 321, No. 1, pp. 17-19, 1988. ✓

EXAMINER	T.A. Solok	DATE CONSIDERED	6/4/03
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Yo	61	Zheng-Nian Huang, "Synthesis and Biological Activities of 1-(substituted pyrazol-4-yl)-1,2,4-triazoles", <i>Chemical Abstracts</i> , Volume 124, No. 23, Abstract No. 317062d, 1996. ✓
	62	Chemical Abstracts, 13 th Collective Chemical Substance Index 1992-1998, Book 51, pp. 546-550. ✓
	63	Zhengming, Li et al., "Syntheses of Di-heterocyclic Compounds; Pyrazolylimidazoles And Isoxazolylimadazoles", <i>Heteroatom. Chem.</i> , Vol. 9, No. 3, pp. 317-320, 1998. ✓
	64	Zheng-Nian Huang, "The Reaction Of α -OXO- α -Triazolyketene Dithioacetal With Amines, Hydrazine And Guanidine", <i>Chinese Chemical Letters</i> , Vol. 5, No. 1, pp. 31-34, 1994. ✓
	65	Popova, A.N. et al., "Synthesis Of 4-(Pyrazol-4-yl)-Substituted Salts Of Pyrylium And Pyridines", <i>Chemical Abstracts</i> , Vol. 098, No. 1, January 3, 1983, Abstract No. 004498. ✓
	66	Bauer, V.J. et al., "4-3(5)-Pyrazolyl Pyridinium Salts. A New Class Of Hypoglycemic Agents", <i>J. Med. Chem.</i> , Vol. 11; pp. 981-4, (September 1968). ✓
	67	Cativiela, C. et al., "On the Synthesis Of 3(5)-(Carbomethoxy)-4-hetarylpyrazoles", <i>J. Heterocycl. Chem.</i> , Vol. 25; pp. 851-5, (May-June 1988). ✓
	68	Fischer, U. et al., "1,3-Dipolar Additions To 7-Methylthieno [2,3-c]pyridine 1,1-dioxide", <i>Helv. Chim. Acta</i> ; Vol. 63(6), No. 180, pp. 1719-27, (1980). ✓
	69	September 24, 1998 PCT International Search Report (PCT/US98/10436) ✓
	70	Badger, Alison M. et al., "Disease-Modifying Activity Of SB 242235, A Selective Inhibitor Of p38 Mitogen-Activated Protein Kinase, In Rat Adjuvant-Induced Arthritis", <i>Arthritis & Rheumatism</i> , Vol. 43, No. 1, pp. 175-183, 2000. ✓
	71	Henry, James R., "p38 Mitogen-Activated Protein Kinase As A Target For Drug Discovery", <i>Drugs of the Future</i> , Vol. 24, pp. 1345-1354, 1999. ✓
	72	Salituro, F.G. et al., "Inhibitors of p38 MAP Kinase: Therapeutic Intervention Cytokine-Mediated Diseases", <i>Current Medicinal Chemistry</i> , Issue 6, pp. 807-823, 1999. ✓
	73	Liverton, N.J. et al., "Design And Synthesis Of Potent, Selective, And Orally Bioavailable Tetrasubstituted Imidazole Inhibitors Of p38 Kinase Mitogen-Activated Protein Kinase", <i>J. Med. Chem.</i> , Vol. 42, pp. 2180-2190, 1999. ✓
	74	Adams, J.L. et al., "Pyrimidinylimidazole Inhibitors Of CSBP/p38 Kinase Demonstrating Decreased Inhibition Of Hepatic Cytochrome p450 Enzymes", <i>Bioorganic & Medicinal Chemistry Letters</i> , Vol. 8, pp. 3111-3116, 1998. ✓
	75	Gallagher, T.F., "Regulation Of Stress-Induced Cytokine Production By Pyridinylimidazoles; Inhibition Of CSBP Kinase", <i>Bioorganic & Medicinal Chemistry</i> , Vol. 5, pp. 49-64, 1997. ✓
	76	Hanson, G.J., "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis", <i>Exp. Opin. Ther. Patents</i> , Vol. 7, pp. 729-733, 1997. ✓
✓	77	Moerck R.E. et al., "Pyrazole Addition To Δ^1 -Azirines. Structure of Purported 2:1 Adducts of Δ^1 -Azirines With sym-Tetrazines", <i>J. Chem. Soc., Chem. Commun.</i> , No. 19, pp. 782-783 (1974). ✓

EXAMINER	T. A. Solala	DATE CONSIDERED	6-4-03
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			